ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable, Trade
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Accounts Payable, Trade of $1.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $816.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $641.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$877.00K, a 130.82% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was $1.31M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2025 was -$1.80M, a 281.53% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2024 was $991.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2023 was -$2.81M, a 153.05% decline from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was $5.29M.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | $816.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.46M 10-Q · filed 2026-08-05 | $580.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $641.00K 10-Q · filed 2026-05-07 | -$236.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.07M derived: sum of 3 quarters · filed 2026-05-07 | $752.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$877.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $432.00K derived: sum of 2 quarters · filed 2026-02-26 | $111.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $988.00K derived: sum of 2 quarters · filed 2026-08-05 | -$922.00K 10-Q · filed 2025-11-06 | $1.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$321.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.23M 10-Q · filed 2026-08-05 | $615.00K derived: sum of 3 quarters · filed 2026-08-05 | $301.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.91M 10-Q · filed 2026-05-07 | $936.00K derived: sum of 2 quarters · filed 2026-05-07 | $622.00K derived: sum of 3 quarters · filed 2026-05-07 | -$264.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.53M derived: sum of 2 quarters · filed 2026-02-26 | $1.65M derived: sum of 3 quarters · filed 2026-02-26 | $991.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$314.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.20M derived: sum of 2 quarters · filed 2025-11-06 | -$1.85M 10-Q · filed 2025-11-06 | $551.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$886.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.54M 10-Q · filed 2025-08-06 | $865.00K derived: sum of 3 quarters · filed 2025-08-06 | -$500.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$655.00K 10-Q · filed 2025-05-08 | $1.75M derived: sum of 2 quarters · filed 2025-05-08 | $386.00K derived: sum of 3 quarters · filed 2025-05-08 | -$3.99M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.04M derived: sum of 2 quarters · filed 2025-02-27 | -$3.34M derived: sum of 3 quarters · filed 2025-02-27 | -$2.81M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$5.75M derived: sum of 2 quarters · filed 2024-11-05 | -$5.21M 10-Q · filed 2024-11-05 | -$618.00K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$4.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$3.85M 10-Q · filed 2024-08-13 | $747.00K derived: sum of 3 quarters · filed 2024-08-13 | -$2.16M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $534.00K 10-Q · filed 2024-05-07 | $5.13M derived: sum of 2 quarters · filed 2024-05-07 | $2.22M derived: sum of 3 quarters · filed 2024-05-07 | $3.76M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.69M derived: sum of 2 quarters · filed 2024-03-13 | $3.23M derived: sum of 3 quarters · filed 2024-03-13 | $5.29M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$1.37M derived: sum of 2 quarters · filed 2023-11-07 | $694.00K 10-Q · filed 2023-11-07 | -$332.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.60M 10-Q · filed 2023-08-08 | $2.58M derived: sum of 3 quarters · filed 2023-08-08 | $2.65M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $2.06M 10-Q · filed 2023-05-10 | $1.03M derived: sum of 2 quarters · filed 2023-05-10 | $1.11M derived: sum of 3 quarters · filed 2023-05-10 | $1.61M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$946.00K derived: sum of 2 quarters · filed 2023-03-06 | -$447.00K derived: sum of 3 quarters · filed 2023-03-06 | -$715.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $579.00K derived: sum of 2 quarters · filed 2022-11-07 | $311.00K 10-Q · filed 2022-11-07 | $233.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $231.00K 10-Q · filed 2022-08-11 | $153.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$268.00K 10-Q · filed 2022-05-12 | -$346.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $631.00K 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $709.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |